Agamree by Purna Pharmaceuticals NV
Agamree by
Drug Labeling and Warnings
Agamree by is a Prescription medication manufactured, distributed, or labeled by Purna Pharmaceuticals NV. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
AGAMREE- vamorolone suspension
Purna Pharmaceuticals NV
----------
DOSAGE AND ADMINISTRATION
The recommended dosage is 6 mg/kg taken orally once daily preferably with a meal, up to a maximum
daily dosage of 300 mg for patients weighing more than 50 kg. (2.2)
In patients with mild to moderate hepatic impairment, the recommended dosage is 2 mg/kg taken
orally once daily preferably with a meal, up to a maximum daily dosage of 100 mg for patients weighing
more than 50 kg. (2.3)
Decrease dosage gradually when administered for more than one week. (2.7)
2.1 Assessments Prior to First Dose of AGAMREE
Administer all immunizations according to immunization guidelines prior to starting
AGAMREE. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to
starting AGAMREE [see Warnings and Precautions (5.8)].
2.2 Dosing Information
The recommended dosage of AGAMREE is 6 mg/kg taken orally once daily preferably
with a meal, up to a maximum daily dosage of 300 mg for patients weighing more than
50 kg.
Some patients may respond to a dose of 2 mg/kg daily. Doses may be titrated down to
2 mg/kg/day as needed, based on individual tolerability.
2.3 Recommended Dosage for Hepatic Impairment
The recommended dosage of AGAMREE in patients with mild (Child-Pugh A) to moderate
(Child-Pugh B) hepatic impairment is 2 mg/kg taken orally once daily preferably with a
meal, up to a maximum daily dosage of 100 mg for patients weighing more than 50 kg
[see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
Doses may be titrated down based on individual tolerability.
2.4 Important Preparation and Administration Instructions
Shake AGAMREE oral suspension well for about 30 seconds before administration.
Use only the oral syringe provided with the product. After withdrawing the appropriate
dose into the oral syringe, dispense directly into the mouth.
Discard any unused AGAMREE oral suspension remaining after 3 months of first
opening the bottle.
2.5 Switching from Corticosteroid Treatment to AGAMREE
Patients can be switched from oral corticosteroid treatment (such as prednisone or
Sections or subsections omitted from the full prescribing information are not listed.
deflazacort) to AGAMREE without treatment interruption or period of prior corticosteroid
dosage reduction to minimize the risk for adrenal insufficiency.
Patients switching after long-term treatment with oral corticosteroids should start
AGAMREE at a dosage of 6 mg/kg/day.
2.6 Dosage Modification for Use with Strong CYP3A4 Inhibitors
The recommended dosage of AGAMREE when administered with strong CYP3A4
inhibitors is 4 mg/kg taken orally once daily preferably with a meal, up to a maximum
daily dosage of 200 mg for patients weighing more than 50 kg [see Drug Interactions
(7.1) and Clinical Pharmacology (12.3)].
Doses may be titrated down based on individual tolerability.
2.7 Discontinuation
Dosage of AGAMREE must be decreased gradually if the drug has been administered for
more than one week [see Warnings and Precautions (5.1)].
DOSAGE FORMS AND STRENGTHS
Oral Suspension: 40 mg/mL (3)
DOSAGE FORMS AND STRENGTHS
Oral Suspension: 40 mg/mL orange flavored white to off-white suspension
CONTRAINDICATIONS
Hypersensitivity to vamorolone or any of the inactive ingredients in AGAMREE (4)
CONTRAINDICATIONS
AGAMREE is contraindicated in patients with known hypersensitivity to vamorolone or to
any of the inactive ingredients of AGAMREE. Instances of hypersensitivity, including
anaphylaxis, have occurred in patients receiving corticosteroid therapy [see Warnings
and Precautions (5.13)].
WARNINGS AND PRECAUTIONS
Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, cushingoid features,
and hyperglycemia can occur. Monitor patients for these conditions with chronic use of AGAMREE. (2.7,
5.1)
Immunosuppression and Increased Risk of Infection: Increased risk of new infections, exacerbation,
dissemination, or reactivation of latent infections, which can be severe and at times fatal; signs and
symptoms of infections may be masked. (5.2)
Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure and monitor sodium
and potassium levels in patients chronically treated with AGAMREE. (5.3)
Gastrointestinal Perforation: Increased risk in patients with certain GI disorders; signs and symptoms
may be masked. (5.4)
Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality
changes, severe depression, and psychosis. (5.5)
Effects on Bones: Monitor for decreases in bone mineral density with chronic use of AGAMREE. (5.6)
Ophthalmic Effects: May include cataracts, infections, and glaucoma; monitor intraocular pressure in
patients chronically treated with AGAMREE. (5.7)
Vaccination: Do not administer live or live attenuated vaccines to patients receiving
immunosuppressive doses of corticosteroids. Administer live-attenuated or live vaccines at least 4 to 6
weeks prior to starting AGAMREE. (5.8)
5 WARNINGS AND PRECAUTIONS
5.1 Alterations in Endocrine Function
Corticosteroids, such as AGAMREE, can cause serious and life-threatening alterations in
endocrine function, especially with chronic use. Monitor patients receiving AGAMREE for
Cushing's syndrome, hyperglycemia, and adrenal insufficiency after AGAMREE
withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or
congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be
at increased risk for adverse endocrine events.
Risk of Adrenal Insufficiency Following Withdrawal
AGAMREE produces reversible hypothalamic-pituitary-adrenal (HPA) axis suppression,
with the potential for the development of secondary adrenal insufficiency after
withdrawal. Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly,
and could be fatal. The degree and duration of adrenocortical insufficiency produced is
variable among patients and depends on the dose and duration of therapy.
The risk of adrenal insufficiency is reduced by gradually tapering the dose when
withdrawing treatment. The insufficiency may persist, however, for months after
discontinuation of prolonged therapy; therefore, in any situation of stress occurring
during that period of discontinuation, supplementation with a systemic corticosteroid is
recommended. For patients already taking corticosteroids during times of stress, the
dosage may need to be increased.
A steroid “withdrawal syndrome”, seemingly unrelated to adrenocortical insufficiency,
may also occur following abrupt discontinuance of corticosteroids. This syndrome
includes symptoms such as anorexia, nausea, vomiting, lethargy, headache, fever, joint
pain, desquamation, myalgia, and/or weight loss. These effects are thought to be due to
the sudden change in corticosteroid concentration rather than too low corticosteroid
levels.
Cushing's Syndrome
Cushing's syndrome (hypercortisolism) occurs with prolonged exposure to exogenous
corticosteroids, including AGAMREE, and symptoms include hypertension, truncal
obesity and thinning of the limbs, purple striae, facial rounding, facial plethora, muscle
weakness, easy and frequent bruising with thin fragile skin, posterior neck fat
deposition, osteopenia, acne, amenorrhea, hirsutism, and psychiatric abnormalities.
Hyperglycemia
Corticosteroids can increase blood glucose, worsen pre-existing diabetes, predispose
those on long-term therapy to diabetes mellitus, and may reduce the effect of antidiabetic
drugs.
Monitor blood glucose at regular intervals in patients treated with AGAMREE. For patients
with hyperglycemia, anti-diabetic treatment should be initiated or adjusted accordingly.
Considerations for Use in Patients with Altered Thyroid Function
Metabolic clearance of corticosteroids is decreased in hypothyroid patients and
increased in hyperthyroid patients. Changes in thyroid status of the patient may
necessitate a dose adjustment of the corticosteroid. When concomitant administration
of AGAMREE and levothyroxine is required, administration of AGAMREE should precede
the initiation of levothyroxine therapy to reduce the risk of adrenal crisis.
Pheochromocytoma Crisis
There have been reports of pheochromocytoma crisis, which can be fatal, after
administration of systemic corticosteroids. In patients with suspected or identified
pheochromocytoma, consider the risk of pheochromocytoma crisis prior to
administering corticosteroids.
5.2 Immunosuppression and Increased Risk of Infection
Corticosteroids, including AGAMREE, suppress the immune system and increase the risk
of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic
pathogens.
Corticosteroids can:
- reduce resistance to new infections
- exacerbate existing infections
- increase the risk of disseminated infections
- increase the risk of reactivation or exacerbation of latent infections
- mask some signs of infection
Corticosteroid-associated infections can be severe, and at times fatal infections can
occur. The rate of infectious complications increases with increasing corticosteroid
dosages.
Corticosteroids cause a dose-dependent increase in lymphocyte and neutrophil counts.
Monitor for the development of infection and consider AGAMREE withdrawal or dosage
reduction as needed.
Varicella Zoster and Measles Viral Infections
Varicella and measles can have a serious or even fatal course in non-immune patients
taking corticosteroids. In corticosteroid-treated patients who have not had these
diseases or are non-immune, particular care should be taken to avoid exposure to
varicella and measles.
- If an AGAMREE-treated patient is exposed to varicella, prophylaxis with varicella
zoster immunoglobulin may be indicated. If varicella develops, treatment with antiviral
agents may be considered.
- If an AGAMREE-treated patient is exposed to measles, prophylaxis with
immunoglobulin may be indicated.
Hepatitis B Virus Reactivation
Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated
with immunosuppressive dosages of corticosteroids. Reactivation can also occur in
corticosteroid-treated patients who appear to have resolved hepatitis B infection.
Screen patients for hepatitis B infection before initiating immunosuppressive (e.g.,
prolonged) treatment with AGAMREE. For patients who show evidence of hepatitis B
infection, recommend consultation with physicians with expertise in managing hepatitis
B regarding monitoring and consideration for hepatitis B antiviral therapy.
Fungal Infections
Corticosteroids may exacerbate systemic fungal infections; therefore, avoid AGAMREE
use in the presence of such infections. For patients on chronic AGAMREE therapy who
develop systemic fungal infections, AGAMREE withdrawal or dosage reduction is
recommended.
Amebiasis
Corticosteroids may activate latent amebiasis. Therefore, it is recommended that latent
amebiasis or active amebiasis be ruled out before initiating AGAMREE in any patient who
has spent time in the tropics or any patient with unexplained diarrhea.
Strongyloides Infestation
Corticosteroids should be used with great care in patients with known or suspected
Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced
immunosuppression may lead to Strongyloides hyperinfection and dissemination with
widespread larval migration, often accompanied by severe enterocolitis and potentially
fatal gram-negative septicemia. For patients on corticosteroids who develop known or
suspected Strongyloides (threadworm) infestation, withdrawal of corticosteroids or
reduction of the dose of corticosteroids is recommended.
5.3 Alterations in Cardiovascular/Renal Function
Corticosteroids, including AGAMREE, can cause elevation of blood pressure, salt and
water retention, and increased excretion of potassium and calcium.
Monitor blood pressure and assess for signs and symptoms of volume overload.
Monitor serum potassium levels.
AGAMREE should be used with caution in patients with congestive heart failure,
hypertension, or renal insufficiency. Literature reports suggest an association between
use of corticosteroids and left free wall rupture after a recent myocardial infarction;
therefore, therapy with AGAMREE should be used with great caution in these patients.
5.4 Gastrointestinal Perforation
There is an increased risk of gastrointestinal perforation with use of corticosteroids in
patients with certain gastrointestinal disorders, such as active or latent peptic ulcers,
diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs of
gastrointestinal perforation, such as peritoneal irritation, may be masked in patients
receiving corticosteroids.
Avoid AGAMREE if there is a probability of impending perforation, abscess, or other
pyogenic infections; diverticulitis; fresh intestinal anastomoses; or active or latent peptic
ulcer.
5.5 Behavioral and Mood Disturbances
Potentially severe psychiatric adverse reactions may occur with systemic
corticosteroids, including AGAMREE. Symptoms typically emerge within a few days or
weeks of starting treatment and may be dose-related. These reactions may improve
after either dose reduction or withdrawal, although pharmacologic treatment may be
necessary.
In Study 1, psychiatric adverse reactions were reported in 21% of patients on AGAMREE
6 mg/kg, 10% of patients on AGAMREE 2 mg/kg, and 14% of patients on placebo.
Psychiatric adverse reactions reported on AGAMREE resolved without requiring
treatment or drug discontinuation.
In adults, psychiatric adverse reactions with corticosteroids usually involve hypomanic
or manic symptoms (e.g., euphoria, insomnia, mood swings) during treatment and
depressive episodes after discontinuation of treatment. In children receiving
corticosteroids, psychiatric adverse reactions usually involve hyperactivity symptoms
(e.g., irritability, aggressive behavior, increased frequency of tantrums, and mood
swings) and sleep disorder during treatment. Inform patients or caregivers of the
potential for behavioral and mood changes and encourage them to seek medical
attention if psychiatric symptoms develop, especially if depressed mood or suicidal
ideation is suspected.
5.6 Effects on Bones
Decreased Bone Mineral Density
Corticosteroids, such as AGAMREE, decrease bone formation and increase bone
resorption both through their effect on calcium regulation (i.e., decreasing absorption
and increasing excretion) and inhibition of osteoblast function. This, together with a
decrease in the protein matrix of the bone secondary to an increase in protein
catabolism and reduced sex hormone production, may lead to inhibition of bone growth
in pediatric patients and the development of bone loss at any age. Bone loss can
predispose patients to vertebral and long bone fractures.
Consider a patient's risk of osteoporosis before initiating corticosteroid therapy. Monitor
bone mineral density in patients on long-term treatment with AGAMREE.
Avascular Necrosis
Corticosteroids may cause avascular necrosis.
5.7 Ophthalmic Effects
The use of corticosteroids, such as AGAMREE, may produce posterior subcapsular
cataracts. Corticosteroids may also cause glaucoma with possible damage to the optic
nerves, and may increase the risk of secondary ocular infections caused by bacteria,
fungi, or viruses. Corticosteroids are not recommended for patients with active ocular
herpes simplex. Intraocular pressure may become elevated in some patients taking
corticosteroids. If treatment with AGAMREE is continued for more than 6 weeks,
monitor intraocular pressure.
5.8 Immunizations
Administer all immunizations according to immunization guidelines prior to starting
AGAMREE. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to
starting AGAMREE. Patients on AGAMREE may receive concurrent vaccinations, except
for live-attenuated or live vaccines.
5.9 Effects on Growth and Development
Long-term use of corticosteroids, including AGAMREE, can have negative effects on
growth and development in children.
5.10 Myopathy
Patients receiving corticosteroids and concomitant therapy with neuromuscular blocking
agents (e.g., pancuronium) or patients with disorders of neuromuscular transmission
(e.g., myasthenia gravis) may be at increased risk of developing acute myopathy. This
acute myopathy is generalized, may involve ocular and respiratory muscles, and may
result in quadriparesis. Clinical improvement or recovery after stopping corticosteroids
may require weeks to years.
5.11 Kaposi's Sarcoma
Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid
therapy, most often for chronic conditions. Discontinuation of treatment may result in
clinical improvement of Kaposi's sarcoma.
5.12 Thromboembolic Events
Observational studies have shown an increased risk of thromboembolism (including
venous thromboembolism) particularly with higher cumulative doses of corticosteroids.
It is unclear if risk differs by daily dose or duration of use. Use AGAMREE with caution in
patients who have or may be predisposed to thromboembolic disorders.
5.13 Anaphylaxis
Rare instances of anaphylaxis have occurred in patients receiving corticosteroid
therapy.
ADVERSE REACTIONS
The most common adverse reactions (>10% for AGAMREE and greater than placebo) are cushingoid
features, psychiatric disorders, vomiting, weight increased, and vitamin D deficiency. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals, Inc. at 1-
844-347-3277 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6 ADVERSE REACTIONS
The following serious adverse reactions are discussed in more detail in other sections:
- Alterations in Endocrine Function [see Warnings and Precautions (5.1)]
- Immunosuppression and Increased Risk of Infection [see Warnings and Precautions
(5.2)]
- Alterations in Cardiovascular/Renal Function [see Warnings and Precautions (5.3)]
- Gastrointestinal Perforation [see Warnings and Precautions (5.4)]
- Behavioral and Mood Disturbances [see Warnings and Precautions (5.5)]
- Effects on Bones [see Warnings and Precautions (5.6)]
- Ophthalmic Effects [see Warnings and Precautions (5.7)]
- Immunizations [see Warnings and Precautions (5.8)]
- Effects on Growth and Development [see Warnings and Precautions (5.9)]
- Myopathy [see Warnings and Precautions (5.10)]
- Kaposi's Sarcoma [see Warnings and Precautions (5.11)]
- Thromboembolic Events [see Warnings and Precautions (5.12)]
- Anaphylaxis [see Warnings and Precautions (5.13)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction
rates observed in the clinical trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates observed in practice.
Common Adverse Reactions in Clinical Studies
Table 1 lists the adverse reactions that occurred in ≥ 5% of the patients treated with
AGAMREE 6 mg/kg/day (N=28) or AGAMREE 2 mg/kg/day (N=30) and that occurred
more frequently than in the patients who received placebo (N=29) in Study 1 [see Clinical
Studies (14)], which was 24 weeks and included patients with DMD between the ages of
4 and 7 years.
Table 1: Adverse Reactions in Patients with DMD that Occurred in ≥ 5% of
Patients Treated with AGAMREE and More Frequently than in Patients Who
Received Placebo During 24 Weeks (Study 1)
| Adverse Reaction | AGAMREE
2 mg/kg/d (N=30)% | AGAMREE
6 mg/kg/d (N=28)% | Placebo
(N=29)% |
| Cushingoid Features | 7 | 29 | 0 |
| Psychiatric disorders1 | 7 | 21 | 14 |
| Vomiting | 17 | 14 | 7 |
| Weight increased | 0 | 11 | 3 |
| Vitamin D deficiency | 7 | 11 | 0 |
| Cough | 10 | 7 | 3 |
| Headache | 7 | 7 | 3 |
| Diarrhea | 3 | 7 | 3 |
| Increased appetite | 3 | 7 | 3 |
| Rhinitis | 3 | 7 | 3 |
1 Includes the following adverse reactions that occurred more frequently in the AGAMREE group
than in placebo: abnormal behavior, aggression, agitation, anxiety, irritability, mood altered, sleep
disorder, and stereotypy.
In a separate open-label safety study of pediatric patients aged 2 to less than 4 years
(n=16) and pediatric patients aged 7 to less than 18 years (n=16) with DMD, adverse
reactions were similar to those seen in the Study 1 pediatric patients.
DRUG INTERACTIONS
Strong CYP3A4 inhibitors: The maximum recommended daily dose is 4 mg/kg up to a maximum daily
dosage of 200 mg for patients weighing more than 50 kg. (2.6, 7.1)
7.1 Effect of Other Drugs on Vamorolone
Co-administration of AGAMREE with itraconazole, a strong CYP3A4 inhibitor, increases
vamorolone exposure [see Clinical Pharmacology (12.3)]. Reduce the dosage of
AGAMREE in patients when strong CYP3A4 inhibitors are used concomitantly [see
Dosage and Administration (2.6)]. No dosage adjustments are required when AGAMREE
is concomitantly administered with moderate or weak CYP3A4 inhibitors.
USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
AGAMREE is indicated for use for the treatment of DMD, which is a disease of young
male patients. However, corticosteroids in general should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus. Infants born to
mothers who have received substantial doses of corticosteroids during pregnancy
should be carefully observed for signs of hypoadrenalism. There are no data on the use
of AGAMREE during pregnancy.
Adverse developmental outcomes, including orofacial clefts (cleft lip, with or without cleft
palate) and intrauterine growth restriction, and decreased birth weight, have been
reported with maternal use of corticosteroids during pregnancy. Some epidemiologic
studies report an increased risk of orofacial clefts from about 1 per 1000 infants to 3 to
5 per 1000 infants; however, a risk for orofacial clefts has not been observed in all
clinical studies. Intrauterine growth restriction and decreased birth weight appear to be
dose-related; however, the underlying maternal condition may also contribute to these
risks (see Clinical Considerations and Data).
Animal reproduction studies have not been conducted with AGAMREE.
Animal reproduction studies conducted with corticosteroids in pregnant mice, rats, hamsters, and rabbits using clinically relevant doses have shown an increased incidence
of cleft palate. An increase in embryofetal death, intrauterine growth retardation, and
constriction of the ductus arteriosus were observed in some animal species.
In the U.S. general population, the estimated background risk of major birth defects and
miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations
Fetal/Neonatal Adverse Reactions
Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during
pregnancy. Infants should be carefully observed for signs of hypoadrenalism, such as
poor feeding, irritability, weakness, and vomiting, and managed accordingly [see
Warnings and Precautions (5.1)].
Data
Human Data
Multiple cohort and case-controlled studies in humans suggest that maternal
corticosteroid use during the first trimester increases the rate of cleft lip, with or without
cleft palate, from about 1/1000 infants to 3-5/1000 infants. Two prospective casecontrolled
studies showed decreased birth weight in infants exposed to maternal
corticosteroids in utero.
8.2 Lactation
Risk Summary
There are no data on the presence of vamorolone in human milk or the effects on milk
production.
AGAMREE is indicated for use for the treatment of DMD, which is a disease of young
male patients. However, systemically administered corticosteroids appear in human milk
and could suppress growth, interfere with endogenous corticosteroid production, or
cause other untoward effects. The developmental and health benefits of breastfeeding
should be considered along with the mother's clinical need and any potential adverse
effects on the breastfed infant.
8.4 Pediatric Use
The safety and effectiveness of AGAMREE for the treatment of DMD have been
established in patients 2 years of age and older. Use of AGAMREE in pediatric patients is
supported by a multicenter, randomized, double-blind, placebo- and active-controlled
study in 121 males 4 to less than 7 years of age [see Clinical Studies (14)]. Use of
AGAMREE in patients 2 years to less than 4 years of age and 7 to less than 18 years of
age is supported by findings of efficacy and safety in patients 4 to less than 7 years of
age with DMD, and by pharmacokinetic and safety data from patients 2 to 4 years of
age and 7 to less than 18 years of age [see Adverse Reactions (6.1) and Clinical
Pharmacology (12.3)].
The safety and effectiveness in pediatric patients below the age of 2 years have not
been established.
Juvenile Animal Toxicity Data
Oral administration of vamorolone (0, 15, 30, or 100 mg/kg/day) to juvenile mice from
postnatal days 21 to 81 resulted in no adverse effects on neurobehavioral function,
sexual maturation, or reproductive function. Atrophy of the adrenal cortex,
degeneration/necrosis of the liver, and decreased lymphocytes in lymphatic tissues were
observed at all doses. A no-effect dose for general toxicity was not identified. Plasma
exposures (AUC) at the lowest dose tested (15 mg/kg/day) were lower than that in
humans at the maximum recommended human dose (300 mg/day).
8.5 Geriatric Use
DMD is largely a disease of children and young adults; therefore, there is no geriatric
experience with AGAMREE.
8.6 Hepatic Impairment
Moderate hepatic impairment increases vamorolone exposure [see Clinical Pharmacology
(12.3)]. Reduce the AGAMREE dosage in patients with mild to moderate hepatic
impairment [see Dosage and Administration (2.3)]. There is no clinical experience with
AGAMREE in patients with severe hepatic impairment, and a dosing recommendation
cannot be provided for patients with severe hepatic impairment.
OVERDOSAGE
10 OVERDOSAGE
Treatment of acute overdosage of vamorolone is by immediate supportive and
symptomatic therapy. Gastric lavage or emesis can be considered.
11 DESCRIPTION
AGAMREE (vamorolone) oral suspension contains vamorolone, a corticosteroid.
Vamorolone [17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione] is a
white to off-white powder with a molecular formula of C H O and a molecular weight
of 356.46 g/mol. Its structural formula is:
Vamorolone is freely soluble in methanol and dioxane and sparingly soluble in ethanol and acetone.
AGAMREE for oral administration is available as an oral suspension in a strength of 40
mg/mL. The oral suspension contains vamorolone and the following inactive ingredients:
citric acid (monohydrate), disodium phosphate, glycerin, hydrochloric acid (for pH
adjustment), orange flavor, sodium benzoate, sucralose, water, and xanthan gum.
CLINICAL PHARMACOLOGY
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Vamorolone is a corticosteroid that acts through the glucocorticoid receptor to exert
anti-inflammatory and immunosuppressive effects. The precise mechanism by which
vamorolone exerts its effect in patients with DMD is unknown.
12.2 Pharmacodynamics
Vamorolone produced a dose-dependent decrease in morning cortisol levels in the
clinical studies. Treatment with corticosteroids is associated with a suppression of
endogenous cortisol concentrations and an impairment of the hypothalamus-pituitaryadrenal
(HPA) axis function. A dose-dependent increase in leukocyte counts and
lymphocyte counts was observed in clinical studies with vamorolone.
Cardiac Electrophysiology
Vamorolone does not cause a mean increase in the QTc interval >20 milliseconds (ms)
at 1.6 times the approved recommended dose.
12.3 Pharmacokinetics
The major route of elimination is by metabolism with subsequent excretion of
metabolites into urine. The pharmacokinetics (PK) are linear and vamorolone exposure
increases proportionally with either single (0.1 to 20 mg/kg) or multiple (0.25 to 20
mg/kg) doses. Vamorolone does not accumulate with repeated administration after once
daily dosing.
Absorption
After oral administration with food, the median T is about 2 hours (range 0.5 to 5
hours).
Effect of Food
Co-administration of vamorolone (2 mg/kg) with a high-fat/high-calorie meal reduced
C by 18%, increased AUC by 13%, and delayed T by one hour. Co-administration
of vamorolone (2 mg/kg) with a low-fat/low-calorie meal reduced C by 4%, increased
AUC by 14%, and delayed T by one hour [see Dosage and Administration (2.2)].
Distribution
The apparent volume of distribution of vamorolone for a DMD patient with a body weight
of 20 kg taking AGAMREE with a meal is 162 L based on the population PK analysis.
Protein binding is 88.1% in vitro. The blood to plasma ratio is approximately 0.87.
Elimination
Vamorolone clearance for a DMD patient with a body weight of 20 kg taking AGAMREE
with a meal is 58 L/h based on the population PK analysis. The terminal elimination halflife
of vamorolone is approximately 2 hours.
Metabolism
Vamorolone is metabolized via multiple Phase I and Phase II metabolic pathways, such
as glucuronidation, hydroxylation, and reduction. The main plasma and urine metabolites
are formed through direct glucuronidation as well as hydrogenation with subsequent
glucuronidation. Metabolism of vamorolone is mediated through CYP3A4/5, CYP2C8,
UGT1A3, UGT2B7, and UGT2B17.
Excretion
Approximately 30% of vamorolone dose is excreted in feces (15.4% unchanged) and
48% of vamorolone dose is excreted in urine as metabolites (<1% unchanged). The
major metabolites in urine are glucuronides.
Specific Populations
No clinically significant differences in the pharmacokinetics of vamorolone were
observed based on race and sex.
Pediatric Patients
In children ages 4 to 7 years (N=12) who were administered 6 mg/kg of AGAMREE daily,
on Day 1 and Day 14, the C values (arithmetic mean, SD) of vamorolone were 856
ng/mL (471) and 970 ng/mL (270), respectively, and the AUC values (arithmetic mean,
SD) of vamorolone were 3279 ng·h/mL (1693) and 3606 ng·h/mL (897), respectively.
The pharmacokinetics of vamorolone was also characterized in DMD children ages 2 to 4
(N=6). Similar PK parameters were observed in younger children after administration of
6 mg/kg AGAMREE when compared to older children.
Patients with Hepatic Impairment
In a clinical study (N=16), vamorolone C and AUC values were increased by
approximately 1.7- and 2.6-fold, respectively, in subjects with moderate hepatic
impairment (Child-Pugh Class B) compared with healthy matched controls [see Dosage
and Administration (2.3) and Use in Specific Populations (8.6)]. There is no experience
with vamorolone in patients with severe hepatic impairment.
Drug Interaction Studies
Effect of Strong CYP3A4 Inhibitors on Vamorolone
Compared to administration of vamorolone alone, administration of vamorolone
following multiple doses of a strong CYP3A4 inhibitor (itraconazole) increased
vamorolone C and AUC by 8% and 44%, respectively [see Drug Interactions (7.1)].
There is no experience with vamorolone when coadministered with moderate and weak
CYP3A4 inhibitors.
In Vitro Studies
Metabolizing Enzymes
Vamorolone induces CYP3A4 in vitro. Other compounds that are substrates of CYP3A4
may have decreased plasma concentrations when co-administered with AGAMREE.
However, no clinical drug interaction studies with CYP3A4 substrates were conducted.
Vamorolone does not inhibit CYP or UGT isoenzymes at clinically relevant concentrations.
Transporter Systems
Vamorolone is not an inhibitor of P-gp, BCRP, OATP1B1, OATBP1B3, OCT2, OAT1, OAT3,
MATE1, MATE2-K, or BSEP at clinically relevant concentrations. Vamorolone is not a
substrate of P-gp, BCRP, OATP1B1, OATBP1B3, OCT2, OAT1, OAT3, MATE1, MATE2-K,
or BSEP.
NONCLINICAL TOXICOLOGY
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
Carcinogenicity studies have not been conducted with vamorolone.
Mutagenesis
Vamorolone was negative for genotoxicity in in vitro (bacterial reverse mutation and
cultured mouse lymphocyte chromosomal aberration) and in vivo (mouse micronucleus)
assays.
Impairment of Fertility
Fertility studies in animals were not conducted with vamorolone. Oral administration of
vamorolone (0, 2, 10, or 50 mg/kg/day) for 39 weeks to dogs resulted in spermatocyte
and spermatid degeneration in the testes and oligospermia and germ cell debris in the
epididymis in males at the high dose and absence of corpora lutea in the ovaries in
females at all doses. Plasma exposures (AUC) in males at the no-effect dose for
testicular toxicity (10 mg/kg) was lower than that at the maximum recommended human
dose of AGAMREE (300 mg/day).
CLINICAL STUDIES
14 CLINICAL STUDIES
The effectiveness of AGAMREE for the treatment of Duchenne muscular dystrophy
(DMD) was evaluated in a multicenter, randomized, double-blind, parallel-group, placeboand
active-controlled, multinational 24-week study (Study 1; NCT03439670). The study
randomized 121 male patients with DMD to one of the following treatment groups:
AGAMREE 6 mg/kg/day (n=30), AGAMREE 2 mg/kg/day (n=30), prednisone 0.75
mg/kg/day (n=31), or placebo (n=30) for 24 weeks. After 24 weeks, patients on
prednisone and placebo received either AGAMREE 6 mg/kg/day (n=29) or AGAMREE 2
mg/kg/day (n=29) for an additional 20 weeks. The study included patients 4 to less than
7 years of age at time of enrollment in the study who were corticosteroid naïve and
ambulatory, with a confirmed diagnosis of DMD. At baseline, patients had a mean age of
5.4 years, 83% were Caucasian, 10% were Asian, and 96% were not Hispanic or Latino.
The primary endpoint was the change from baseline to Week 24 in Time to Stand Test
(TTSTAND) velocity for AGAMREE 6 mg/kg/day compared to placebo. TTSTAND velocity
is a measure of muscle function that measures the time required for the patient to stand
to an erect position from a supine position (floor). The key secondary endpoints
consisted of change from baseline to Week 24 in TTSTAND velocity (AGAMREE 2
mg/kg/day vs placebo), 6 Minute Walk Test (6MWT) distance (AGAMREE 6 mg/kg/day vs
placebo and 2 mg/kg/day vs placebo) and Time to Run/Walk 10 meters (TTRW) velocity
(AGAMREE 6 mg/kg/day vs placebo and 2 mg/kg/day vs placebo). The 6MWT measures
the distance that a patient can walk on a flat, hard surface in a period of 6 minutes and
TTRW measures the time that it takes a patient to run or walk 10 meters. The fixed
sequential testing process was applied to the key secondary endpoints in the order
listed above.
The primary endpoint and key secondary endpoints were met for the AGAMREE 6
mg/kg/day treatment group. The AGAMREE 2 mg/kg/day treatment group was
statistically significant vs. placebo for TTSTAND and 6MWT, but was not statistically
significant vs. placebo for TTRW. See Figure 1 and Table 2 for efficacy results from
Week 24.
Figure 1: Least-Squares Mean Change in Time to Stand (TTSTAND) Velocity (rises/sec)
Table 2: Change from Baseline to Week 24 on TTSTAND, 6MWT, and TTRW
Compared to Placebo
| Parameter | Placebo | AGAMREE
2 mg/kg/d | AGAMREE
6 mg/kg/d |
| TTSTAND velocity
(rises/sec) Baseline Mean change from baseline Difference from placebo (95% CI) p-value | 0.200
-0.012 N/A N/A | 0.184
0.033 0.045 (0.008, 0.082) 0.017 | 0.186
0.048 0.060 (0.023, 0.098) 0.002* |
| 6MWT distance (meters)
Baseline Mean change from baseline Difference from placebo (95% CI) p-value | 355
-14 N/A N/A | 316
27 40 (13, 68) 0.004 | 313
29 42 (16, 69) 0.002 |
| TTRW velocity (meters/sec)
Baseline Mean change from baseline Difference from placebo (95% CI) p-value | 1.735
0.014 N/A N/A | 1.563
0.141 0.127 (-0.026, 0.281) 0.103 | 1.600
0.258 0.244 (0.093, 0.395) 0.002 |
Baseline values are presented with descriptive statistics (mean). Mean changes and differences are model-based least-squares means and mean differences. Positive numbers indicate improvement as compared with the baseline value.
*Primary endpoint
HOW SUPPLIED/STORAGE AND HANDLING
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
AGAMREE oral suspension is an orange flavored homogeneous white to off-white
suspension, containing 40 mg/mL of vamorolone.
AGAMREE is supplied as 100 mL in 125 mL glass bottle packaged with one bottle
adapter, two 5 mL oral syringes, and an Instructions for Use: NDC: 69616-264-38.
16.2 Storage and Handling
Store the bottle upright at room temperature between 20°C to 25°C (68°F to 77°F).
Excursions permitted between 15°C to 30°C (59°F to 86°F) in the original carton. See
USP controlled room temperature.
After opening, store the bottle upright in a refrigerator 2°C to 8°C (36°F to 46°F). Do
not freeze.
Discard any unused AGAMREE oral suspension remaining after 3 months of first
opening the bottle.
Instructions for Use
Read this Instructions for Use before you start using AGAMREE oral suspension and
each time you get a new bottle.
This information does not take the place of talking to your healthcare provider about
your medical condition or treatment.
Supplies provided in the AGAMREE carton:
|  |
Important information you need to know before taking AGAMREE:
- For oral use only (take by mouth).
- Always use the oral syringes provided with your AGAMREE oral suspension to make sure you measure the right amount.
- Ask your healthcare provider or pharmacist to show you how to measure your prescribed daily dose using the oral syringe.
- Call your pharmacist if your oral syringes are lost or damaged.
- Each oral syringe can be used for 45 days. Call your pharmacist if you need more oral syringes.
- Take AGAMREE exactly as your healthcare provider tells you to take it. Do not stop taking AGAMREE suddenly without first speaking with your healthcare provider.
- AGAMREE oral suspension should be taken 1-time daily with a meal.
- Do notmix the AGAMREE oral suspension with any type of liquids before taking or giving the prescribed daily dose.
- Do notuse AGAMREE 3 months after opening the bottle. Write the date of first opening on your AGAMREE bottle when you first open it.
Storing AGAMREE
- Store the unopened bottle upright at room temperature between 68°F to 77°F (20°C to 25°C) in the original carton. After opening the bottle, store the bottle upright in a refrigerator between 36°F to 46°F (2°C to 8°C).
- Do not freeze.
- Throw away (discard) any unused AGAMREE oral suspension remaining after 3 months of first opening the bottle.
Keep AGAMREE oral suspension and all medicines out of the reach of children.
Preparing the AGAMREE bottle
| Step 1 | Place the child-resistant bottle cap on the bottle.
Make sure the child-resistant bottle cap is tightly secured and shake the bottle well for about 30 seconds. |  |
| Step 2 | Open the bottle by firmly pressing down on the child-resistant bottle cap and turning it to the left (counter-clockwise).
Do not throw away the child-resistant bottle cap. |  |
| Step 3 | Place the open bottle on a flat surface.
Firmly insert the bottle adapter into the bottle by pushing it tightly into the top of the bottle. The top edge of the bottle adapter should be even with the bottle top. Do notremove the bottle adapter after it is inserted into the bottle. Write the date of first opening on your AGAMREE bottle when you first open it. |  |
Preparing and withdrawing the AGAMREE dose
| Step 4 | Check your dose in milliliters (mL) as prescribed by your healthcare provider. Each mark on the oral syringe is equal to 0.1 mL.
Do nottake more than the prescribed daily dose. |  |
| Step 5 | Place the bottle on a flat surface.
Before inserting the tip of the oral syringe into the bottle adapter, push the plunger completely down toward the tip of the oral syringe. Use 1 hand to hold the bottle upright. Insert the oral syringe tip firmly into the opening of the bottle adapter. |   |
| Step 6 | Hold the oral syringe in place and carefully turn the bottle upside down.
Pull the plunger down slowly until you reach the mL markings on the plunger for the prescribed dose. Do not pull the plunger out of the oral dispenser. |  |
| Step 7 | If there are large bubbles in the oral syringe or if you draw up the wrong dose of AGAMREE, push the plunger all the way up so that AGAMREE flows back into the bottle. Pull the plunger down slowly until you reach the mL markings for your prescribed dose. Repeat Step 7 if any large air bubbles remain or if you draw up the wrong dose of AGAMREE. |  |
| Step 8 | Leave the tip of the oral syringe in the bottle and turn the entire bottle to an upright position. Slowly remove the oral syringe tip from the bottle by pulling the oral syringe straight up.
Do nothold the oral syringe by the plunger, because the plunger may come out. Take or give AGAMREE right away after it is drawn up into the oral syringe. Do not store the filled oral syringe. |  |
Taking AGAMREE
| Step 9 | The child or adult should sit
upright to take a dose of AGAMREE. Place the oral syringe tip in the mouth towards the cheek and slowly push the plunger down until the oral syringe is empty. Do not forcefully push on the plunger. Do not give AGAMREE too fast into the back of the mouth or throat. This may cause choking. |  |
| step 10 | If your prescribed dose is
greater than 5 mL, repeat Steps 4 to 9. |
After taking or giving AGAMREE
| step 11 | Put the child-resistant bottle
cap back on the bottle and turn the cap to the right (clockwise) to close the bottle. Keep the bottle tightly closed after each use. |  |
Cleaning the oral syringes
| step 12 | Remove the plunger from the
barrel of the oral syringe. Rinse the barrel and plunger with running warm water only and let them air dry on a paper towel. When the oral syringe and plunger are dry, put the plunger back in the oral syringe for the next dose. Store the oral syringe in a clean, dry place. |  |
For further information call 1-833-422-8259 or go to www.YourCatalystPathways.com.
Manufactured for: Catalyst Pharmaceuticals, Inc., Coral Gables, FL 33134
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Approved: 10/2023
Advise the patients and/or caregivers to read the FDA-approved patient labeling
(Instructions for Use).
Administration
Warn patients and/or caregivers to not stop taking AGAMREE abruptly or without
first checking with their healthcare providers as there may be a need for gradual
dose reductions to decrease the risk of adrenal insufficiency crisis [see Dosage and
Administration (2.7) and Warnings and Precautions (5.1)].
AGAMREE oral suspension should be taken once daily, preferably with a meal.
AGAMREE oral suspension must be shaken well for about 30 seconds prior to
measuring out each dose with the enclosed oral syringe.
Discard any unused AGAMREE oral suspension remaining after 3 months of first
opening the bottle.
Immunosuppression and Increased Risk of Infection
Tell patients and/or caregivers to inform their healthcare provider if the patient has had
recent or ongoing infections or if they have recently received a vaccine. Medical advice
should be sought immediately if the patient develops fever or other signs of infection.
Patients and/or caregivers should be made aware that some infections can potentially be
severe and fatal.
Warn patients who are on corticosteroids to avoid exposure to chickenpox or measles
and to alert their healthcare provider immediately if they are exposed [see Warnings and
Precautions (5.2)].
Alterations in Cardiovascular/Renal Function
Inform patients and/or caregivers that corticosteroids, including AGAMREE, can cause
an increase in blood pressure and water retention. If this occurs, dietary salt restriction
and potassium supplementation may be needed [see Warnings and Precautions (5.3)].
Behavioral and Mood Disturbances
Advise patients and/or caregivers about the potential for severe behavioral and mood
changes with AGAMREE and encourage them to seek medical attention if psychiatric
symptoms develop [see Warnings and Precautions (5.5)].
Decreases in Bone Mineral Density
Advise patients and/or caregivers about the risk of osteoporosis with prolonged use of
AGAMREE, which can predispose the patient to vertebral and long bone fractures [see
Warnings and Precautions (5.6)].
Ophthalmic Effects
Inform patients and/or caregivers that AGAMREE may cause cataracts or glaucoma and
advise monitoring if administered for more than 6 weeks [see Warnings and Precautions
(5.7)].
Vaccination
Advise patients and/or caregivers to bring immunizations up-to-date according to
immunization guidelines prior to starting therapy with AGAMREE. Live-attenuated or live
vaccines should be administered at least 4 to 6 weeks prior to starting AGAMREE.
Inform patients and/or caregivers that they may receive concurrent vaccinations with
use of AGAMREE, except for live-attenuated or live vaccines [see Warnings and
Precautions (5.8)].
Drug Interactions
Certain medications can cause an interaction with AGAMREE [see Drug Interactions
(7.1)]. Advise patients and/or caregivers to inform their healthcare provider of all the
medicines the patient is taking, including over-the-counter medicines (such as insulin,
aspirin or other NSAIDS), dietary supplements, and herbal products. Inform patients
and/or caregivers that alternate therapy, dosage adjustment, and/or special test(s) may
be needed during the treatment.
Manufactured for:
Catalyst Pharmaceuticals, Inc.
Coral Gables, FL 33134, USA
AGAMREE Oral Suspension made in Italy
AGAMREE is a registered trademark of Santhera Pharmaceuticals (Schweiz) AG.
| AGAMREE
vamorolone suspension |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
| Labeler - Purna Pharmaceuticals NV (372126946) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Purna Pharmaceuticals NV | 372126946 | manufacture(62450-003) | |
Trademark Results [Agamree]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 AGAMREE 90499828 not registered Live/Pending |
Santhera Pharmaceuticals (Schweiz) AG 2021-01-31 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.